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Background: Apolipoprotein E (APOE) genotype (2/3/4: rs429358 4 allele; rs7412 2 allele) is strongly associatedwith both lipid levels
and Alzheimer’s disease. Although there is also evidence of milder cognitive impairment in later life in carriers of the APOE 4 allele, there
have been few studies investigating the impact of APOE genotype on cognitive function in children.
Methods: We determined APOE genotype in 5995 children from the Avon Longitudinal Study of Parents and Children and investigated
associations between APOE genotype and plasma lipids (at age 9), IQ (at age 8), memory (at ages 8 and 10), and performance in school
attainment tests (at ages 7, 11, and 14).
Results: Observed genotype group counts were consistent with Hardy–Weinberg equilibrium (2 p value  .84). There were strong
elationships between APOE genotype and low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides,
hich follow the samepatterns as in adults. Therewasno strongevidence to suggest thatAPOEgenotypewas associatedwith IQ (allp values
.46), memory function (p .35), or school attainment test results (p .28).
onclusion: Although APOE genotype does have strong associations with lipid levels in childhood, there does not seem to bemeaningful
ffects on cognitive performance, suggesting that any detrimental effects of the 4 allele on cognitive function are not important until later
ife.
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T here are two well-known coding polymorphisms of apolipo-protein E (APOE), resulting in arginine cysteine amino acidchanges at positions 130 (rs429358) and 176 (rs7412). These
hanges determine alleles 2/3/4, having frequencies of 8%,
8%, and 14%, respectively, in the UK population (1). The APOE 4
llele represents a major susceptibility factor for late onset Alzhei-
er’s disease (LOAD), with carriers having approximately a three-
old risk (over tenfold for homozygotes) of developing LOAD com-
ared with noncarriers (2,3). The mechanism linking APOE
genotype and LOAD remains obscure, although isoform-depen-
dent effects on  amyloid deposition and clearance, synaptic sig-
naling, and inflammatory responses have been reported (4,5).
The APOE 4 allele might also be associated with domain-spe-
cific cognitive decline in normal aging (6–14). Memory decline in
particular has been noted in several studies, including one study of
almost 6000 elderly adults (15), as beingmoremarked in 4 carriers
(12,15–17). A recent model predicted that long-term memory de-
cline in 4 carriers began at age 50–60 years compared with age
70–80 years innoncarriers (12). Beginningat approximately age45,
persons who carry the APOE 4 allele demonstrate an accelerated
evolution of regional brain LOAD changes according to Braak crite-
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doi:10.1016/j.biopsych.2010.10.033ia (18). However, the effects of the APOE genotype on cognitive
unctioning in adulthood are inconsistent. Jorm et al. (19) found no
trong evidence for an effect of 4 allele carriage on cognitive
unction in 6560 adults ranging in age from 20 to 64 years, and in a
eta-analysis of data from 38 studies of participants ages 45 years
nd above, 4 carriers exhibited minor reductions in global cogni-
ive functioning, episodic memory, and executive functioning.
owever, the observed differences were.1 SD units (20).
Given that the domains of cognitive function that have demon-
trated association with APOE genotype are similar to the early
igns of LOAD and the timing of the onset of this cognitive decline,
t has been suggested that 4-related cognitive decline might be
aused by preclinical LOAD (13). However, the three common iso-
orms of APOE havemajor effects on lipoprotein fractions and sub-
equent risk of cardiovascular disease (21) as well as drug prescrib-
ng (22). Individuals with the 4 allele tend to have higher levels of
otal and low-density lipoprotein cholesterol (LDLc) and lower lev-
ls of high-density lipoprotein cholesterol (HDLc) than noncarriers.
or triglycerides a U-shaped distribution is observed, with 3 ho-
ozygotes having the lowest levels and 4 and 2 heterozygotes
aving intermediate levels and 4 and 2 homozygotes having the
ighest levels. Thus, it is possible that associations between APOE
enotype and cognitive function outside of LOADmight also have
ascular origins. The APOE 4 allele has been shown to be a risk
actor for ischemic cerebrovascular disease (23).
The influence of APOE alleles on cognition at an early agewould
e of particular interest, because it would potentially aidmechanis-
ic understanding. Therehavebeen relatively fewstudies ofAPOE in
elation to cognition in children;most of these have been small and
hereforeof limitedpower todetect differencesbetween individual
enotype groups. Deary et al. (24), in a retrospective study of 173
articipants in the Lothian study, found no difference in perfor-
ance by 4 carrier status in the Moray House IQ test at age 11
ears, and Turic et al. (25) similarly found no differences in APOE
enotype distribution in 101 high-IQ and 101 average-IQ children.
BIOL PSYCHIATRY 2011;70:152–158
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A.E. Taylor et al. BIOL PSYCHIATRY 2011;70:152–158 153In a study of 109 11–16-year-olds in California, Bloss et al. (26) found
some evidence that cognitive functionwas lower only in 4 carriers
who also had a family history of Alzheimer’s disease. However, in
children, total spatiotemporal wave activity patterns have been
shown to differ between 3 homozygotes and 4 carriers (27). In
ddition, a magnetic resonance imaging study of 239 healthy chil-
ren showed that 4 carriers had lower cortical thickness in the left
ntorhinal region of the brain compared with noncarriers (27).
here is also evidence that the 4 allelemight actually beprotective
or brain development and cognitive function in early childhood.
nfants carrying the 4 allele performed better in mental develop-
ent tests in a study inMexico, and amongst children in Brazil, who
ad had heavy diarrhea burdens in their first 2 years of life, 4
arriers showed better verbal fluency than noncarriers (28,29). This
as led some to hypothesize that 4might be an example of antag-
nistic pleiotropy, with the 4 allele being beneficial in early life but
etrimental later in life (29,30). This could be due to the higher
holesterol levels seen in 4 carriers, because cholesterol is essen-
ial for neurodevelopment (31).
The purpose of this study was to obtain more precise estimates
f the effects of all sixAPOEgenotypes on cognitive performance in
hildhood, in the context of the prevailing childhood blood lipid
rofile. We analyzed APOE genotype in relation to IQ at age 8,
emory tasks at ages 8 and 10, and school age educational perfor-
ance tests (at ages 7, 11, and 14) in children from the ALSPAC
tudy (AvonLongitudinal Studyof Parents andChildren). In parallel,
e analyzed the APOE genotype in relation to plasma lipid profiles.
Methods andMaterials
Study Population
The ALSPAC study (http://www.bristol.ac.uk/alspac) is a pro-
spective study, established to explore child health and develop-
ment (32). The initial ALSPAC sample consisted of 14,541 pregnant
women fromBristol, United Kingdom,with expected delivery dates
between April 1991 and December 1992, resulting in 14,062 live
births. At age 7, a further 548 eligible children were added to the
sample, making a total sample size of 14,610 for analyses. Detailed
information on the children has been collected via questionnaires
since birth and at annual clinic visits since the age of 7.
Genotyping
DNA Samples. Deoxyribonucleic acid samples were available
for this study for 7091 children (63% of the 11,343 ALSPAC children
with DNA samples available). Genotyping of the three main allelic
variants (3, 4, and 2) of APOE was undertaken by integrated
single-label liquidphase assay. Full details of themethodhavebeen
published previously (1). Polymerase chain reaction products were
analyzed with a 384-well LightTyper instrument (Roche Diagnos-
tics, GmbH, Indianapolis, Indiana), andgenotypeswere determined
with Light-Typer software, Ver. 1. DuplicateDNAsamples (identities
unknown during genotyping) were analyzed to validate the assay,
and a random sample (of 100 wells) was called independently by
two investigators as a validation of genotype calling.
Lipids. Nonfasting blood sampleswere takenduring clinic visit
at age 9 (age range 8.8–11.7 years). Plasma lipids (total cholesterol,
triglycerides, and HDLc) were measured by modification of the
standard Lipid Research Clinics Protocol with enzymatic reagents
for lipid determinations (33). The LDLc was estimated with the
Friedewald equation (34).
Cognitive FunctionMeasures
ClinicAssessments. The IQwasmeasuredat a clinic heldwhenthe children were 8.5 years of age (mean: 8.7 years; range: 7.5–9.4 hears) with the Wechsler Intelligence Scale for Children (35). A
horter version of the scale was used in which alternate items (al-
ays starting with Item 1 on the standard form) were used for 9 of
0 subtests. Scores from the verbal and performance subscales
ere used as outcome measures as well as overall IQ score. A
easure of speech and language, the Wechsler Objective Lan-
uage Dimensions (WOLD) test (36) was administered at the same
linic. Reading levelwas assessedat clinic at age7.5 years (mean: 7.5
ears; range: 6.9–8.0 years) with measures based on the Wechsler
bjective Reading Dimensions (WORD) test (37).
Short-term memory at age 8 was measured in clinic with an
daptation of the Nonword Repetition Test (38). Children were
sked to repeat 12 nonsense words of three, four, and five syllables
fter hearing them on an audio cassette. The outcome measure is
he number of words repeated correctly. Working memory at age
0 was assessed in clinic via the Counting Span Working Memory
ask (39). This test involved counting and recalling numbers of dots
n screens, whichwere administered in sets of two, three, four, and
ve screens. Twoscoreswere recorded fromthis test; the span score
epresents the number of correctly recalled sets, with a maximum
core of 5 in increments of .5, and the global score represents the
otal number of screens correct, with a maximum of 42 (40).
School Assessments. In addition to clinic measures of cogni-
ive function,weused the results of nationally administered school-
ased tests (SATS) (for more detailed information see website:
ttp://curriculum.qcda.gov.uk/). These are undertaken in Year 2
key stage 1, age 6–7 years), Year 6 (key stage 2, age 10–11 years),
nd Year 9 (key stage 3, age 13–14 years). For key stage 1, English
reading and writing) and math scores were categorized into three
roups: below average (W, 1), average (2a, 2b, 2c), and above aver-
ge (3) on thebasis of the expectedattainment for this agegroup.
or key stages2and3, total scoresobtained in the tests for the three
ore subjects (English, math, and science) were used as the out-
ome measure.
tatistical Analysis
Individuals of known nonwhite ethnic origin (n  547) were
xcluded from all analyses.Where siblings andmultiple birthswere
resent, the first-born in the study was kept, and the others (n 
72) were dropped from all analyses.
Hardy–Weinberg equilibrium tests were performed on the en-
ire sample of genotyped children (excluding siblings and those of
onwhite ethnicity) and on the samples with available lipid or cog-
itive function measures to assess the possibility of sampling bias
ue to nonattendance at clinic.
Means and SDs of total cholesterol, LDLc, and HDLc levels were
alculated for each genotype. Geometric means and interquartile
anges are presented for triglycerides, due to skewed distributions.
Age- (in months) and gender-adjusted associations between
enotypes and total cholesterol; LDLc; HDLc; triglycerides (log-
ransformed); total, verbal, and performance IQ; WORD and WOLD
cores; memory tests; and key stage 2 and 3 test scores were as-
essed by linear regression. In all regression models, each APOE
enotype was considered separately with 3 homozygotes as the
eference group. Heterogeneity of associations of APOE genotypes
ith each outcomewere assessed by analysis of covariancemodels
nd p values reported. Chi-square tests were used to look at associ-
tions between APOE genotypes and key stage 1 test results. Direct
ssociations between plasma lipids (as continuous variables and in
uartiles) and cognitive functionmeasures were assessed by linear
egression, adjusted for age, gender, and maternal education and
ousehold socioeconomic status.
www.sobp.org/journal
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Ethical approval was obtained from the ALSPAC Law and Ethics
Committee and local research ethics committees. Parental consent
and assent of the child were obtained for all measurements made.
Results
In total, 95% of samples were successfully genotyped. The num-
berof childrenwithgenotype informationavailable for theanalyses
was 5995, after excluding children of known nonwhite ethnicity
and siblings. Lipid measures on a subset of 2875 of those geno-
typed and IQ measures for a subset of 3925 of those genotyped
wereavailable. Therewasno strongevidenceof agenderdifference
in genotype distribution (p  .16) or of deviation from Hardy–
Weinberg equilibrium for the whole sample (2 1.42, p .84) or
hen the samplewas restricted to childrenwith genotype and lipid
ata (n  2875, 2  4.53, p  .34) or genotype and IQ data (n 
3925, 2 1.97, p .74).
Lipids
Levels of total cholesterol and LDLc increased according to the
number of 4 alleles and decreased according to the number of 2
alleles (p  .0001) (Table 1). Conversely, levels of HDLc decreased
according to the number of 4 alleles and increased according to
the number of 2 alleles (p .0001). A U-shaped curve was found
for triglycerides where levels increased according to the number of
2 and 4 alleles. Tables S1 (male subjects) and S2 (female subjects)
in Supplement 1 describe lipid levels in relation to APOE genotype
for boys and girls. Girls demonstrated higher levels of total, LDLc,
and triglycerides.
Lipids and IQ
Information on lipids and IQ was available for 3713 children
(Table 2). The IQ decreased by .93 points for each mmol/L increase
in LDLc (p  .04), but this attenuated to .58 points (p  .15) after
djustment for maternal education and household social class. The
254 children who had APOE information demonstrated a similar
attern. Associations of quartiles of lipid measures with IQ and
ipids (as continuous measures and quartiles) with other cognitive
unction measures are shown in Tables S3–S5 in Supplement 1.
Individuals in the second and fourth quartiles of LDLc demon-
trated lower IQ scores than those in the lowest quartile, but these
ssociations did attenuate after adjustment formaternal education
nd social class (Table S3 in Supplement 1). There was some evi-
ence that being in the highest quartiles of either total cholesterol
r LDLc was associated with lower scores in key stage 2 math and
he nonword repetition memory test (Table S5 in Supplement 1).
hese associations remained after adjustment for maternal educa-
ion and household socioeconomic position.
ognitive Function
There was little evidence to suggest that IQ, WORD, and WOLD
est results were associated with APOE genotype (Table 3). How-
ever, on each measure, children who carried 2/2 and 4/4 geno-
ypes tended to have slightly higher scores. For example, total IQ
as 3.6 points higher for children who carried 2/2 compared with
hose who carried 3/3 and 2.6 points higher for 4/4 compared
ith 3/3. Memory scores, including nonword repetition task re-
ults, were not associated with APOE genotype (Table 4). The SATS
scores were essentially unrelated to APOE genotype (Table 5 and
able S6 in Supplement 1).
However, therewas a consistent pattern that 2/2 and 4/4 girls
ad higher IQ scores (from 3 to 7 points) compared with 3/3 girls
Table S7 in Supplement 1). These genotypes were also associated
www.sobp.org/journalTa
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A.E. Taylor et al. BIOL PSYCHIATRY 2011;70:152–158 155ith SATS scores among girls (Table S8 in Supplement 1); this pat-
ern was less evident among boys.
iscussion
Wehaveundertaken a composite analysis includingAPOEgeno-
ype and serum lipid, IQ, and educational measures in a large pop-
lation-based sample of children. Lipid profiles differed by APOE
enotype in characteristic patterns corresponding with the wider
iterature, which has largely focused on adults (21). There was
trong statistical evidence for these genotype-specific differences
n total cholesterol, HDLc, triglycerides, and calculated LDLc, and
he data definewith high precision the population patterns for this
e, Gender-Adjusted All Adjustedb
95% CI p Coeffa (IQ points) 95% CI p
.46, .09) .08 .45 (1.17, .26) .22
.79, .06) .04 .59 (1.38, .21) .15
.74, 1.60) .93 .27 (1.82, 1.27) .73
.64, 1.73) .37 .35 (.74, 1.44) .53
.78, .23) .13 .70 (1.64, .23) .14
.10, .15) .09 .85 (1.89, .20) .11
.95, 1.38) .48 .64 (2.65, 1.37) .53
.37, 2.67) .14 .62 (.80, 2.03) .39
crease in lipid measure.
able 4. Scores in Memory Tests at Ages 8 and 10 by APOE Genotype
Coefficienta 95% CI pb
onWord Repetition Task,
n 3937
2/2 .43 (.49, 1.35)
2/3 .06 (.30, .18)
2/4 .08 (.58, .41)
3/3 — —
3/4 .09 (.28, .11)
4/4 .08 (.62, .46) .86
ounting Span Task Global Score,
n 3667
2/2 .83 (3.56, 1.90)
2/3 .02 (.73, .77)
2/4 .30 (1.29, 1.89)
3/3 — —
3/4 .32 (.28, .92)
4/4 .98 (.79, 2.75) .75
ounting Span Task Span Score,
n 3667
2/2 .11 (.42, .20)
2/3 .001 (.08, .08)
2/4 .02 (.16, .20)
3/3 — —
3/4 .05 (.02, .12)
4/4 .18 (.02, .37) .35
Nonword repetition task from age 8 clinic, counting span task from age
0 clinic. APOE, apolipoprotein E; CI, confidence interval.
aTable 2. Associations of Plasma Lipids with Total IQ
Ag
Coeffa (IQ points)
ll Children, n 3713
Total cholesterol (mmol/L) .69 (1
LDLc (mmol/L) .92 (1
HDLc (mmol/L) .07 (1
Triglyceridec (mmol/L) .54 (
Children with APOE Genotype Data, n 2254
Total cholesterol (mmol/L) .78 (1
LDLc (mmol/L) .98 (2
HDLc (mmol/L) .79 (2
Triglyceridec (mmol/L) 1.15 (
Abbreviations as in Table 1.
aCoefficients from linear regression represent increase in IQ points/mmol/L in
bAge, gender, maternal education, household social class adjusted.Table 3. Associations of APOE Genotype with IQ, WORD, and WOLD Tests
Coeffa 95% CI pb
Total IQc, n 3925
2/2 3.62 (2.20, 9.44)
2/3 .29 (1.24, 1.83)
2/4 .85 (2.34, 4.04)
3/3 — —
3/4 .13 (1.10, 1.35)
4/4 2.61 (.87, 6.09) .58
Verbal IQc, n 3938
2/2 3.86 (2.04, 9.77)
2/3 .07 (1.63, 1.48)
2/4 .30 (2.94, 3.53)
3/3 — —
3/4 .37 (1.61, .88)
4/4 2.24 (1.29, 5.77) .58
Performance IQc, n 3940
2/2 2.78 (3.29, 8.85)
2/3 .83 (.76, 2.43)
2/4 1.27 (2.06, 4.60)
3/3 — —
3/4 .93 (.35, 2.21)
4/4 2.41 (1.22, 6.04) .46
WORDd, n 4391
2/2 1.46 (1.59, 4.50)
2/3 .31 (1.15, .52)
2/4 .44 (2.21, 1.33)
3/3 — —
3/4 .27 (.94, .40)
4/4 1.02 (.92, 2.96) .64
WOLDd, n 3940
2/2 .36 (.35, 1.06)
2/3 .03 (.21, .15)
2/4 .08 (.29, .46)
3/3 — —
3/4 .06 (.21, .09)
4/4 .28 (.14, .69) .56
APOE, apolipoprotein E; WORD, Wechsler Objective Reading Dimen-
sions; WOLD, Wechsler Objective Language Dimensions; CI, confidence
interval.
aFrom linear regression adjusted for gender and the age of child in
months.
bThe p values for heterogeneity from analysis of covariance model.
c Adjusted for age and gender.
bThe p values for heterogeneity from analysis of covariance model.
www.sobp.org/journal
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156 BIOL PSYCHIATRY 2011;70:152–158 A.E. Taylor et al.age group and era in the UK. By contrast, despite known associa-
tions of APOE genotypewith cognitive decline in adults and Alzhei-
mer’s disease, no differences were evident for the main genotype
groups for IQ, memory, and educational measures of children, al-
though there were possible differences for rare genotype sub-
groups.
The total and LDLc values for the different genotypes in our
cohort (age 9) are similar although slightly lower than the average
values observed in a population based-sample of 3–18-year-olds in
Finland in 1980 and a sample of 11-year-old Greek schoolchildren
(41,42). A study on the same Finnish population found that the
characteristic differences in lipid levels by APOE genotype were
present at age 3 but not in newborns, suggesting that these asso-
ciations develop in the first few years of life (43). For HDLc level,
genotype differences were less marked in our sample than differ-
ences in LDLc and total cholesterol, but there was clear evidence of
an increasewith 2 alleles and a decreasewith 4 alleles, whichwas
not obvious in the Finnish population (41). The lipid data act as a
ositive control for our genotyping and database operations, con-
rming that the absence of association with cognitive measures in
ur study does not reflect technical limitations.
Becauseof thewide rangeof cognitive functionmeasures inves-
igated within ALSPAC (both clinic measures and the results of
ationally administered tests), our study provides good evidence
hat having an 4 allele is not detrimental to cognitive performance
n childhoodor adolescence. This studywas sufficiently powered to
etect differences of 1.9 and 2.0 IQ points in 4/3 and 2/3 geno-
ypes, respectively, comparedwith 3homozygotes but only differ-
nces of 5.1 and 8.5 IQ points in 4 and 2 homozygotes, respec-
ively. Furthermore, it might be expected that the 4 allele would
ave an additive effect on cognitive function (i.e., having one 4
llele has aweaker effect thanhaving two), but the effects are in the
ame direction—as is demonstrated for both lipids and LOAD
Table 5. Key Stage 2 and 3 Test Scores by APOE Genotype
Key Stage 2
n Coeffa 95% CI
English n 5245
2/2 46 3.26 (1.22, 7.74)
2/3 704 .76 (2.02, .51)
2/4 141 .39 (2.98, 2.21)
3/3 3019 — —
3/4 1218 .64 (1.66, .38)
4/4 117 .38 (3.22, 2.46)
ath n 5263
2/2 45 3.79 (2.29, 9.87)
2/3 709 .59 (2.28, 1.10)
2/4 140 1.06 (4.56, 2.44)
3/3 3031 — —
3/4 1222 .78 (2.15, .59)
4/4 116 2.02 (5.85, 1.81)
cience n 5310
2/2 44 3.32 (.22, 6.86)
2/3 713 .47 (1.43, .50)
2/4 141 .04 (1.97, 2.05)
3/3 3067 — —
3/4 1228 .52 (1.30, .27)
4/4 117 .46 (1.73, 2.65)
APOE, apolipoprotein E; CI, confidence interval.
aFrom linear regression adjusted for gender and age at testing in month
bThe p values for heterogeneity from analysis of covariance model.21,44)—but we did not observe this pattern in our results. In addi- f
www.sobp.org/journalion, the 2 allele did not exert any effect in the common 2/3
eterozygote group. This lack of association with cognitive func-
ionmeasures in ALSPAC is consistent with the findings of previous
maller studies in children of a similar age (24,25) and suggests that
he preclinical effects of Alzheimer’s disease do not start in child-
ood. The human ancestral allele for APOE is widely accepted to be
4, the sequence observed in other primates and from which two
equential mutations at CpG sites representing arginine codons
12 and 158 have respectively generated alleles 3 and 2, under
utative positive selection (45). The maximal biological contrast
hould therefore be between 4 and 2, and the absence of differ-
nce in our study argues against cognitive function in earlier life
eing a selective pressure.
It might be, as is suggested by the results of studies of normal
ognitive aging in older adults, that APOE is only associated with
ertain domains of cognitive function, and so general measures
uch as IQ and attainment tests have not captured specific differ-
nces. However, memory function, one of the domains that has
ost commonly been found to be associated with APOE genotype
n older people (12,46), did not differ between APOE genotype
roups at ages 8 and 10.
The minor homozygote groups (4/4 and 2/2) displayed the
reatest magnitude associations (both positive) with IQ, and 2/2
omozygotes also displayed the greatest magnitude associations
ith key stage 2 test scores, especially in girls (Tables S7 and S8 in
upplement 1). Given the small numbers in these groups, the con-
dence intervals are wide and are consistent with there being no
ffect. However, the results might suggest some cognitive advan-
age in thesegroups. Sucha scenario couldbebiologically plausible
f lipid levels during childhood affect brain development, a hypoth-
sis that has been put forward with regard to the 4 allele and
holesterol levels and for which there is some evidence in the
iterature (28,29). Lipid levels are affected both by environmental
Key Stage 3
n Coeffa 95% CI pb
n 4487
2/2 42 3.33 (1.85, 8.50)
2/3 618 .51 (.98, 2.00)
2/4 122 .74 (2.35, 3.82)
3/3 2566 — —
3/4 1036 .06 (1.16, 1.29)
4/4 103 .32 (3.02, 3.67) .83
n 4607
2/2 43 1.27 (5.20, 7.73)
2/3 632 1.38 (3.25, .48)
2/4 125 .99 (4.84, 2.87)
3/3 2644 — —
3/4 1054 .22 (1.31, 1.75)
4/4 109 .13 (4.24, 3.98) .72
n 4635
2/2 43 2.86 (10.05, 4.34)
2/3 633 .98 (1.10, 3.05)
2/4 127 .89 (3.37, 5.14)
3/3 2661 — —
3/4 1063 1.31 (.39, 3.01)
4/4 108 2.89 (1.70, 7.49) .46pb
.45
.52
.28actors, suchasdiet, andbygenetic variants suchasAPOE. TheAPOE
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A.E. Taylor et al. BIOL PSYCHIATRY 2011;70:152–158 157genotype therefore acts as a genocopy for environment-affected
lipid levels. Among rare lipoprotein disorders, microsomal triglyc-
eride transfer protein genocopies the effects on the central nervous
systemof both genetic- and environment-driven forms of vitamin E
deficiency (47–49). Higher triglyceride levels are observed in both
4 and 2 carriers compared with 3/3 (Table 1) and numerous
mportant substances such as polyunsaturated fatty acids (50),
almitate (51), fish oils (i.e., N-3 fatty acids) (52), and fat-soluble
itamins such as vitamin E (47)—which have recognized impor-
ance in brain development—are also carried by lipoprotein parti-
les. Further studies would be required with larger numbers in the
inor homozygote groups to obtain robust conclusions for them.
Our genetic observations are consistent with the attenuation of
he association between LDLc and IQ (Table 2), after adjustment for
he confounding factors maternal education and socioeconomic
lass. Previous studies in young andmiddle-age adults (53,54) have
uggested associations between lipid measures and intellectual
erformance. However, no consistency between phenotypes
which included immediate and delayedword recall, fluid and crys-
allized intelligence) or studies has emerged. We have analyzed by
uartiles of lipid measures (Tables S3 and S5 in Supplement 1) to
ook for U-shaped relationships as well as by regression on the
ssumption of a monotonic quantitative association (Table 2 and
able S4 in Supplement 1). Overall, the most apparent positive
ndings (e.g., lower non–word repetition score inhigher LDLcquar-
iles)wereattenuatedafter adjustment for confounding factors and
esidual effects were inconsistent (e.g., lower IQ in second and
ourth quartiles of LDLc comparedwith the first and third). It would
e possible in the future, with a large number of genetic variants
nfluencing LDLc (55), to useMendelian randomization tests (56) of
hether there is causal association between circulating LDLc and
ognitive function.
We found some evidence of an interaction between genotype
ndgender in the IQ analyses,which raises thepossibility thatAPOE
enotype might have a different effect on cognitive function in
ale subjects and female subjects.MortensenandHogh (9) founda
ecline in IQ scores in 4 carriers from age 70 to 80 in women but
ot men, although the study sample comprised only 163 people.
owever, although associations between APOE genotype were
tronger when our analyses were stratified by gender than in the
ample as a whole, there was no consistent pattern across the
ifferent cognitive measures, and evidence for these associations
ould not remain after Bonferroni correction for the number of
tatistical tests performed. Thus, support for a gender difference in
he association between cognitive measures and APOE is limited.
In conclusion, although the estimates for the homozygote
roups are less precise, due to relatively small numbers we can be
onfident that—at least for the three major genotype groups (3/
3, 3/4, and 2/3) that represent 94% of this population—APOE
enotype has no major influence on cognition in childhood and
dolescence. However, given the strong associationswith lipid pro-
les in these children, APOE genotype should be considered impor-
ant in the context of the origins of cardiovascular disease.
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